Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 26 of 115, showing 5 Applications out of 571 total, starting on record 126, ending on 130

# Protocol No Study Title Investigator(s) & Site(s)

126.

ECCT/24/02/02   Sabin 003
    A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults   
Principal Investigator(s)
1. Prof. Videlis Nduba Nzioka
Site(s) in Kenya
KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya
 
View

127.

ECCT/24/02/06   INAVO122
    A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CA‐mutated HER2‐positive locally advanced or metastatic breast cancer   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

128.

ECCT/24/02/09   pionERA
    This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of   giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor   (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal   growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant   endocrine therapy.   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

129.

ECCT/24/01/03   Doxy Short Course
    A Phase 4 Study of a 3-Day Vs. 7-Day Regimen of Doxycycline for the Treatment of Chlamydial Infection.   
Principal Investigator(s)
1. Jackson Nyangaresi Nyandoro
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Pwani Research Centre (Mombasa county)
2. KEMRI CCR-PHRD (Nairobi City county)
 
View

130.

ECCT/24/01/01   SAVIS
    A Phase 1 Clinical Study to Evaluate the Safety and Immunogenicity of a Novel GMMA Vaccine Against Invasive Non-Typhoidal Salmonella in healthy Kenyan adults.      
Principal Investigator(s)
1. ANTHONY SCOTT
Site(s) in Kenya
KEMRI Centre for Geographical Medicine Research Coast
 
View